Holen Sie sich die Stockscreener-App
17.32
24.20%
3.29
Schlusskurs vom Vortag:
$14.03
Offen:
$15.5
24-Stunden-Volumen:
10.60M
Relative Volume:
5.46
Marktkapitalisierung:
$1.52B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-95.90M
KGV:
-13.12
EPS:
-1.32
Netto-Cashflow:
$-79.09M
1W Leistung:
+102.85%
1M Leistung:
+111.73%
6M Leistung:
+397.86%
1J Leistung:
+145.42%
1-Tages-Spanne:
$15.50
$18.75
1-Wochen-Bereich:
$7.8691
$18.75
52-Wochen-Spanne:
$1.865
$18.75
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Vergleichen Sie TERN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
17.35 | 1.23B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.94 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.37 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
425.56 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.58 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.41 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday - Benzinga
Terns Pharma (TERN) Receives Price Target Raise to $28 by Truist - GuruFocus
Terns Pharmaceuticals stock price target raised to $22 at BMO on strong ASH data - Investing.com Nigeria
Terns Pharmaceuticals stock extends gain after positive CML drug data - Investing.com
Terns Pharmaceuticals stock hits 52-week high at 16.41 USD - Investing.com
Terns Pharma (TERN): Barclays Raises Price Target by 92.86% | TE - GuruFocus
Mizuho Boosts Price Target on Terns Pharmaceuticals to $32 From $9, Keeps Outperform Rating - MarketScreener
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 - Investing.com Australia
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Targe - GuruFocus
Terns Pharmaceuticals (TERN) Upgraded with Increased Price Target Following Promising Data - GuruFocus
Terns Pharmaceuticals stock rating upgraded to Buy by H.C. Wainwright - Investing.com
Terns Pharma (TERN) Upgraded to Buy by HC Wainwright & Co. | TER - GuruFocus
Terns Pharmaceuticals stock price target raised by Truist on CML drug data - Investing.com South Africa
Price momentum metrics for Terns Pharmaceuticals Inc. explainedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Relative strength of Terns Pharmaceuticals Inc. in sector analysisMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
Terns Pharmaceuticals (TERN) Is Up 74.1% After Positive Phase 1 TERN-701 Data in CML Patients - Yahoo Finance
Combining price and volume data for Terns Pharmaceuticals Inc.Dollar Strength & Growth Oriented Trade Recommendations - newser.com
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Quarterly Growth Report & Verified Short-Term Trading Plans - newser.com
Terns Pharmaceuticals (TERN) Pivots After TERN-601 Setback Can a Focus on Oncology Redefine Its Future? - simplywall.st
After GLP-1 drug falters, Terns Pharmaceuticals shifts focus to cancerBizwomen - The Business Journals
Terns Pharma (TERN) Upgraded to Outperform by William Blair | TE - GuruFocus
Oppenheimer raises Terns Pharmaceuticals stock price target to $24 on promising leukemia drug data - Investing.com Australia
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform By Investing.com - Investing.com Australia
Biotech Deals And Breakthroughs Spark Heavy Trading Across Markets - Finimize
Pharmaceutical Stocks To Add to Your WatchlistNovember 3rd - MarketBeat
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades - Benzinga
Terns reports 64% MMR rate in phase 1 CML trial with TERN-701 By Investing.com - Investing.com South Africa
William Blair upgrades Terns Pharmaceuticals stock rating to Outperform - Investing.com
Terns Pharmaceuticals (TERN) Upgraded After Promising Clinical T - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy By Investing.com - Investing.com Philippines
Terns Pharmaceuticals (TERN) Presents Promising Data from CARDINAL Trial - GuruFocus
Terns Pharmaceuticals stock soars on promising data for CML therapy - Investing.com
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting - The Manila Times
Terns Pharmaceuticals Announces Positive Data from CARDINAL Trial - TradingView
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML ... - Bluefield Daily Telegraph
Will Terns Pharmaceuticals Inc. stock recover after recent dropPortfolio Return Report & Consistent Profit Trade Alerts - newser.com
Sector ETF performance correlation with Terns Pharmaceuticals Inc.Trade Entry Summary & Low Risk Entry Point Tips - newser.com
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stockMarket Trend Review & High Conviction Buy Zone Picks - newser.com
Should you hold or exit Terns Pharmaceuticals Inc. nowTrade Ideas & Intraday High Probability Setup Alerts - newser.com
Real time breakdown of Terns Pharmaceuticals Inc. stock performanceQuarterly Performance Summary & Target Return Focused Stock Picks - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stockWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsMarket Sentiment Review & Technical Entry and Exit Alerts - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Portfolio Value Report & Real-Time Market Trend Scan - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceM&A Rumor & Long-Term Safe Return Strategies - newser.com
What does recent volatility data suggest for Terns Pharmaceuticals Inc.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Terns Pharmaceuticals Inc Stock Analysis and ForecastSwing Trading Watchlist & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):